Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Iacovelli, F. Pietrantonio, A. Farcomeni, C. Maggi, A. Palazzo, F. Ricchini, F. Braud, M. Bartolomeo (2014)Chemotherapy or Targeted Therapy as Second-Line Treatment of Advanced Gastric Cancer. A Systematic Review and Meta-Analysis of Published Studies
PLoS ONE, 9
H. Ford, A. Marshall, J. Bridgewater, T. Janowitz, F. Coxon, J. Wadsley, W. Mansoor, D. Fyfe, S. Madhusudan, G. Middleton, D. Swinson, S. Falk, I. Chau, D. Cunningham, Paula Kareclas, N. Cook, J. Blazeby, J. Dunn (2014)Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.
The Lancet. Oncology, 15 1
M. Ychou, V. Boige, J. Pignon, T. Conroy, O. Bouché, G. Lebreton, M. Ducourtieux, L. Bedenne, J. Fabre, B. Saint‐Aubert, J. Genève, P. Lasser, P. Rougier (2011)Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 13
J. Macdonald, S. Smalley, J. Benedetti, S.A Hundhal, N. Estes, G.N Stemmermannn, D. Haller, J. Ajani, L. Gunderson, J. Jessup, J. Martenson (2002)Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
The New England journal of medicine, 345 10
P. Thuss-Patience, A. Kretzschmar, D. Bichev, T. Deist, A. Hinke, K. Breithaupt, Y. Doğan, B. Gebauer, G. Schumacher, P. Reichardt (2011)Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
European journal of cancer, 47 15
H. Espejo (1996)[Gastric cancer].
Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru, 16 1
H. Ford, I. Gounaris (2015)Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma
Therapeutic Advances in Gastroenterology, 8
S. Hironaka, S. Ueda, H. Yasui, T. Nishina, M. Tsuda, T. Tsumura, N. Sugimoto, H. Shimodaira, S. Tokunaga, T. Moriwaki, T. Esaki, M. Nagase, K. Fujitani, K. Yamaguchi, T. Ura, Y. Hamamoto, S. Morita, I. Okamoto, N. Boku, I. Hyodo (2013)Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 35
T. Janowitz, P. Thuss-Patience, A. Marshall, J. Kang, Claire Connell, N. Cook, J. Dunn, S. Park, H. Ford (2016)Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data
British Journal of Cancer, 114
C. Fuchs, J. Tomasek, Cho Yong, Filip Dumitru, R. Passalacqua, C. Goswami, H. Safran, L. Santos, G. Aprile, D. Ferry, B. Melichar, M. Tehfé, E. Topuzov, J. Zalcberg, I. Chau, W. Campbell, C. Sivanandan, J. Pikiel, M. Koshiji, Y. Hsu, A. Liepa, L. Gao, J. Schwartz, J. Tabernero (2014)Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
The Lancet, 383
AD Wagner, S Unverzagt, W Grothe, G Kleber, A Grothey, J Haerting (2010)Chemotherapy for advanced gastric cancer
Cochrane Database Syst Rev, 3
Yo‐Han Cho, S. Yoon, Soo-Nyung Kim (2016)Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis
Cancer Research and Treatment : Official Journal of Korean Cancer Association, 49
JH Kang, SI Lee, DH Lim, KW Park, SY Oh, HC Kwon (2012)Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone
J Clin Oncol, 30
A. Ferro, B. Peleteiro, M. Malvezzi, C. Bosetti, P. Bertuccio, F. Levi, E. Negri, C. Vecchia, N. Lunet (2014)Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype.
European journal of cancer, 50 7
S. Al-Batran, E. Jäger, M. Scholz (2007)Chemotherapy for advanced gastric cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 6
G. Roviello, C. Pacifico, K. Polom, F. Roviello, D. Generali (2016)Different efficacy of ramucirumab in patients with metastatic gastric and gastroesophageal junction cancer according to ECOG performance status.
Annals of oncology : official journal of the European Society for Medical Oncology, 28 3
K. Shitara, K. Muro, Y. Shimada, S. Hironaka, N. Sugimoto, Y. Komatsu, T. Nishina, K. Yamaguchi, Y. Segawa, Y. Omuro, T. Tamura, T. Doi, S. Yukisawa, H. Yasui, F. Nagashima, M. Gotoh, T. Esaki, M. Emig, K. Chandrawansa, A. Liepa, H. Wilke, Y. Ichimiya, A. Ohtsu (2016)Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer
Gastric Cancer, 19
D. Cunningham, W. Allum, S. Stenning, J. Thompson, C. Velde, M. Nicolson, J. Scarffe, F. Lofts, S. Falk, T. Iveson, David Smith, R. Langley, M. Verma, S. Weeden, Y. Chua, MAGIC Participants (2006)Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
The New England journal of medicine, 355 1
E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, Lawrence Rubinstein, L. Shankar, L. Dodd, Robert Kaplan, D. Lacombe, J. Verweij (2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
European journal of cancer, 45 2
H. Wilke, K. Muro, E. Cutsem, S. Oh, G. Bodoky, Y. Shimada, S. Hironaka, N. Sugimoto, O. Lipatov, Tae-You Kim, D. Cunningham, P. Rougier, Y. Komatsu, J. Ajani, M. Emig, R. Carlesi, D. Ferry, K. Chandrawansa, J. Schwartz, A. Ohtsu (2014)Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
The Lancet. Oncology, 15 11
J. Thigpen (2012)Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
Yearbook of Oncology, 2012
Background Ramucirumab—alone or combined with paclitaxel—represents one of the main options for patients failing first-line treatment for advanced gastric cancer. Objective The RAMoss study aimed to evaluate the safety and efficacy profile of ramucirumab in the “real-life setting”. Patients and Methods Patients from 25 Italian hospitals started therapy consisting of ramucirumab 8 mg/kg i.v. d1,15q28 with or without paclitaxel 80 mg/m i.v. d1,8,15q28. The primary endpoint was safety, and secondary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results One hundred sixty-seven patients with disease progression on first-line therapy received ramucirumab as monotherapy (10%) or combined with paclitaxel (90%). Median treatment duration was 4 months (1–17 months). Global incidence of grade (G) 3–4 toxicity was 9.6%, and for neutropenia 5.4%; treatment was discontinued due to toxicity in 3% of patients. The most frequent adverse events (AE) were G1–2 fatigue (27.5%), G1–2 neuropathy (26.3%), and G1–2 neutropenia (14.9%). ORR was 20.2%. Stable disease was observed in 39.2% of patients, with a disease control rate of 59.4%. With a median follow-up of 11 months, median PFS was 4.3 months (95% confidence interval [CI] 4.1–4.7), whereas median OS was 8.0 months (95% CI: 7.09–8.9). In a multivariate
Targeted Oncology – Springer Journals
Published: Mar 27, 2018
Access the full text.
Sign up today, get DeepDyve free for 14 days.